The FDA grants rare pediatric disease designation for serious or life-threatening diseases that affect fewer than 200,000 people in the United States when those people are primarily younger than 18 ...
Nivolumab plus AVD “should be a strong candidate for primary treatment in adolescent and adult patients with stage III or IV Hodgkin’s lymphoma,” according to researchers.